The global Cell and Gene Therapy Manufacturing Market is worth US$ 19.3 Billion as of now and expected to reach US$ 240 Billion by the year 2033 at a staggering CAGR of 29% between 2023 and 2033.
The changing landscape of treating chronic ailments through advanced therapies is the key factor driving the cell and gene therapy manufacturing market. The key players have expanded their manufacturing capabilities regarding vector production and have also undertaken several strategic initiatives for producing investigational therapies. Along these lines, BioCardia Inc., in April 2022, did declare that the US FDA approved its IND applications for Covid-19 stem cell therapy to treat patients recovering from Acute Respiratory Distress owing to SARS-CoV-2.
As of May 2022, ~300 cell and gene therapies are under clinical trial and expected to grow on a significant count in the years to come.
Research states that nearly 35% of process gets outsourced with conventional biologics and over 65% of the production process for gene and cell therapies gets outsourced. This could be reasoned with the fact that almost 67% of innovations regarding the space is gone through by small firms lacking expertise, capacity, and resources to commercialize the products.
Future Market Insights has walked through these facts with future perspectives in its latest market study entitled ‘Cell and Gene Therapy Manufacturing market’. The line of expertise in the form of analyst and consultants is there to execute through bottom-up approach.
“With advanced therapies transforming paradigm of treatment in several rare and life-threatening diseases along with reshaping biopharmaceutical vertical, the global cell and gene therapy manufacturing market is slated to witness an atrocious growth going forward”, says an analyst from Future Market Insights.
Key Companies Profiled:
Thermo Fisher Scientific, Merck KGaA, Lonza, Catalent Inc., Takara Bio Inc., F. Hoffmann-La Roche Ltd, Wuxi Advanced Therapies, Samsung Biologics, Boehringer Ingelheim, Novartis AG, Hitachi Chemical Co., Ltd., Cellular Therapeutics, Miltenyi Biotec, Bluebird Bio Inc.
Get More Insights@ https://www.futuremarketinsights.com/reports/cell-and-gene-therapy-manufacturing-market
Market Segments Covered in Cell and Gene Therapy Manufacturing Market Analysis
By Therapy Type:
- Cell Therapy Manufacturing
- Stem Cell Therapy
- Non-Stem Cell Therapy
- Gene Therapy Manufacturing
By Scale:
- Pre-commercial/ R&D Manufacturing
- Commercial Scale Manufacturing
By Mode:
- Contract Manufacturing
- In-house Manufacturing
By Workflow:
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical And Quality Testing
- Raw Material Testing
- Vector Production
- Other Workflows